The Australian 'FORM' approach to guideline development: The quest for the perfect system by Dahm, Philipp & Djulbegovic, Benjamin
COMMENTARY Open Access
The Australian ‘FORM’ approach to guideline
development: The quest for the perfect system
Philipp Dahm
1, Benjamin Djulbegovic
2*
Abstract
Background: Clinical practice guidelines have been defined as systematically developed statements to assist
practitioner and patient decision-making about appropriate health care for specific clinical circumstances. They play
an important role in guiding evidence based clinical practice. The Australian National Health and Medical Research
Council has developed and pilot-tested a new framework for guideline development, the FORM approach, the role
of which has yet to be further defined.
Methods: We critically review the elements of the FORM approach and compare it to other, more established
methods for rating the quality of evidence and strength of recommendations.
Results: FORM recognizes five factors that impact the strength of a recommendation which are the evidence base,
consistency, clinical impact, generalizability and applicability. Consideration of these elements leads to a four-tiered
rating system represented by the letters A ("body of evidence can be trusted to guide practice”) to D ("body of
evidence is weak and recommendation must be applied with caution”). It builds on other existing guideline
methodologies such as those developed by the Scottish Intercollegiate Guidelines Network (SIGN), the Strength of
Recommendation Taxonomy (SORT) and the Grading of Recommendations Assessment, Development and
Evaluation (GRADE) groups. FORM distinguishes itself from other systems by its strong emphasis on applicability,
which is separated out as its own category and relates the relevance of the body of evidence to the Australian
healthcare system.
Conclusions: The FORM approach offers a methodologically rigorous alternative approach to guideline
development that places particular emphasis on aspects of applicability. This feature is unique and may prompt
future adoption by other guidelines systems
Commentary
Clinical practice guidelines have been defined as system-
atically developed statements to assist practitioner and
patient decision-making about appropriate health care
for specific clinical circumstances [1]. Alongside with
efforts to systematically draw together the entire body
of evidence for a specific clinical question as promoted
by the Cochrane Collaboration [2] and the evidence-
based medicine movement with its emphasis on critical
appraisal [3], the guideline movement has been one of
the driving forces towards a more evidence-based prac-
tice of medicine. Clinical practice guidelines also hold a
prominent position in the hierarchy of evidence-based
resources, as they link evidence with decision-making
for a given clinical condition at the point of care [4].
Since their humble beginnings in the early nineties, the
defining characteristics of clinical practice guidelines that
can rightfully consider themselves “evidence-based” have
increasingly been developed [5]. These include a formal
r a t i n go ft h eq u a l i t yo ft h ee v i d e n c et h a tg o e sb e y o n d
study design alone and considers to what extent metho-
dological safeguards against bias (such as allocation con-
cealment, blinding, drop-out rates etc) are put in place to
minimize the risk of bias. Early on, there was little con-
sensus on how to rate the quality of evidence, and by
2002 there were 106 competing evidentiary systems avail-
able [6]. However, basing evidentiary rules on study
design alone yielded unsatisfactory results when it came
to guiding the action for clinical decision-makers, thereby
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tems to develop clinical practice guidelines [7]. This gen-
eration of methodological frameworks is represented by
those currently used by the U. S. Preventive Services
Task Force (USPSTF), the National Institute for Health
and Clinical Excellence (NICE), the Scottish Intercollegi-
ate Guidelines Network (SIGN), the Strength of Recom-
mendation Taxonomy (SORT) and the Grading of
Recommendations Assessment, Development and Eva-
luation (GRADE) groups. A major contribution of these
systems has been the recognition that factors other than
the quality of evidence alone impact clinical recommen-
dations, thereby prompting a clear separation of the qual-
ity of evidence from the strength of a recommendation.
The FORM framework represents a new arrival of an evi-
dence-based methodology to develop clinical practice
guidelines [8]. It clearly acknowledges its roots in the SIGN
and SORT systems, which were adapted to meet the per-
ceived needs of stakeholder organization representatives in
the Australian healthcare system. In brief, it recognizes five
factors that impact the strength of a recommendation
which are the evidence base, consistency, clinical impact,
generalizability and applicability. Consideration of these
elements then leads to a four-tiered rating system repre-
sented by the letters A ("body of evidence can be trusted to
guide practice”) to D ("body of evidence is weak and
recommendation must be applied with caution”).
Although this system is novel, it should be recognized
that it differs little from the existing guidelines systems.
For example, when comparing FORM with GRADE,
which is used by more than 55 organizations in 23 coun-
tries, “clinical impact” refers to the likely benefit that
application of the guideline can realize while also taking
into account the relevance of the effect to patients (clini-
cal importance), precision and effect size [9]. GRADE
considers all of these elements in operationally different
ways- it starts with the clinical importance of the out-
comes, takes into account the magnitude of the effect
and its precision as part of the evaluation of quality of
evidence and assesses the ratio of benefit to harm (which
GRADE considers one of three other dimensions distinct
from the quality of evidence) in formulation of the guide-
line recommendations [10]. However, what distinguishes
FORM from other systems is its strong emphasis on
applicability, which is separated out as its own category
and relates the relevance of the body of evidence to the
Australian healthcare system. This feature is unique and
may prompt future adoption by other guidelines systems.
In an ideal world, guidelines developers would employ
a unified system to rate the quality of evidence and
strengths of recommendations [11]. Doing so would dis-
pel the “Babylonian confusion” among users trying to
make sense of the varying terminology and definitions
used by various guidelines developers, ultimately helping
to enhance guidelines implementation [12]. To date, no
such unified system exists and we are confronted with a
fairly large number of competing systems that fail to
readily translate one into another [13].
H o ws h o u l dw ea r r i v ea tt h e“best” system? To do so,
one would ultimately like to show that a) the system
results in making recommendations that will lead to bet-
ter outcomes than recommendations by other systems
and b) the system is more reproducible than others. The
first point will be difficult to prove empirically and may
therefore remain forever unresolved. The second point
relates to the issue of whether a system such as FORM
can be operationalized in terms of practical, reproducible
policy and procedures. To illustrate the challenge, con-
sider the number of combinations that can arise from the
FORM system that (as shown in table 1 in the manu-
script) distinguishes between five factors that can be
rated in four different ways thereby resulting in 4
5 =
1024 combinations. These must be considered in con-
junction with recommendations that are made using a
four-tiered scale for or against an intervention (4
2 =1 6
combinations). This results in a mind-boggling 16,384
(1024 × 16) ways in which a body of evidence can theore-
tically be categorized to support clinical recommenda-
tions. It is, however, highly likely that some combinations
are more prevalent than others making development of
the guidelines system more feasible than these theoretical
calculations appear to indicate. Nevertheless, it is also
likely that this complexity, hitherto only implicitly
acknowledged by the people in the field, drives the efforts
to develop new systems for guidelines development. It is
also clear that as we strive to develop a unified guidelines
s y s t e m ,w em u s tf i n daw a yt or a t eab o d yo fe v i d e n c e
and strength of recommendations in a reproducible and
reliable manner. We believe that the most important
next step in the EBM field relates to the need to perform
empirical methodological research to evaluate which of
the existing guidelines systems is most reproducible and
performs best in the hands of the individuals they are
meant to serve. Without undertaking this research, the
entire evidence-based medicine edifice may lose its solid
ground, built so carefully over the last 20 years.
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